“Maximizing the power of proteomic clinical trial profiling for better, actionable insights – a new collaborative initiative from the SCALLOP consortium”
In this webinar, SCALLOP consortium founder, Anders Mälarstig describes a new initiative that aims to maximize the statistical power of early phase clinical trial data through a collaborative approach:
Hear how SCALLOP studies over the past 4 years have identified correlative and causal protein biomarkers for common complex diseases.
Learn how protein quantitative trait loci (pQTLs) identified via proteogenomic studies, combined with systematic Mendelian randomization analysis, can identify novel drug targets based on the confident assessment of causality in the diseases of interest.
Hear about a new clinical trial arm for SCALLOP, a pre-competitive collaboration aimed at studying dynamic protein changes over time and increasing the statistical power of proteomic profiling data from phase I/II trials.
Understand the value of this collaborative approach in overcoming the challenges of small sample sizes in early clinical trials, enabling new insights into the mechanism of action, safety endpoints, and response stratification for investigational new drugs.
To access this webinar, as well as the rest of our categorized library of more than 20 high-quality scientific webinars featuring presentations by leading researchers in their respective fields, please click the button below.
Dr. Mälarstig received his Ph.D. in cardiovascular genetics from Uppsala University in 2006 and then did postdoctoral training at the Karolinska Institute in Stockholm. In 2009 he joined Pfizer, where he is now director of Target Sciences. In his current role, he is responsible for developing and applying strategies for new drug targets and precision medicine. He has extensive experience working in international academic consortia and public-private partnerships such as the SCALLOP consortium, which recently published their first article in Nature Metabolism, entitled “Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals.”